Biosenta Inc (TSE:ZRO)
:ZRO
Want to see TSE:ZRO full AI Analyst Report?
Top Page
Biosenta Inc
(ZRO)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.05
▼(-40.00% Downside)
Action:UpgradedDate:04/23/26
The score is driven primarily by very weak financial performance (shrinking small revenue base, persistent losses, negative operating/free cash flow, and deeply negative equity). Technicals also remain bearish with the stock below major moving averages, partially offset by oversold momentum readings. Valuation is difficult to support due to a negative P/E and no dividend data.
Positive Factors
Improving free cash flow burn
Free cash flow burn improved versus 2024 annual levels, reducing near-term financing pressure. If sustained, this extends operational runway and lowers dilution risk, providing management more time to stabilize operations or execute restructuring over the next several months.
Negative Factors
Deeply negative shareholders' equity
Deeply negative equity (~-10.6M) against a tiny asset base (~92K) indicates accumulated deficits dominate capital structure. This structural insolvency constrains access to capital, limits strategic options, and creates a high risk of dilution or recapitalization needs absent material improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving free cash flow burn
Free cash flow burn improved versus 2024 annual levels, reducing near-term financing pressure. If sustained, this extends operational runway and lowers dilution risk, providing management more time to stabilize operations or execute restructuring over the next several months.
Read all positive factors
Biosenta Inc (ZRO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.74M
Dividend YieldN/A
Average Volume (3M)2.93K
Price to Earnings (P/E)―
Beta (1Y)2.35
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
EmployeesN/A
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)N/A
Shares Outstanding34,768,887
10 Day Avg. Volume5,790
30 Day Avg. Volume2,930
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-0.40
Price to Sales (P/S)3296.23
P/FCF Ratio-8.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biosenta Inc Business Overview & Revenue Model
Company Description
Biosenta Inc. develops, manufactures, and sells anti-microbial chemical compounds for household and industrial applications in Canada. It is involved in developing true, an anti-microbial, dual-action disinfectant that kills viruses, bacteria, mol...
How the Company Makes Money
null...
Biosenta Inc Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
7
Very Negative
Cash Flow
9
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.21K | 1.38K | 1.04K | 1.15K | 168.10K |
| Gross Profit | -1.78K | 835.00 | 427.00 | 728.00 | 99.11K |
| EBITDA | -1.39M | -1.09M | -6.24M | -1.24M | -2.03M |
| Net Income | -2.51M | -2.23M | -6.30M | -1.46M | -2.05M |
Balance Sheet | |||||
| Total Assets | 110.33K | 113.54K | 107.59K | 256.08K | 263.66K |
| Cash, Cash Equivalents and Short-Term Investments | 26.49K | 8.53K | 5.88K | 27.26K | 111.88K |
| Total Debt | 694.59K | 5.55M | 5.62M | 94.77K | 152.43K |
| Total Liabilities | 10.17M | 7.99M | 7.96M | 3.18M | 2.86M |
| Stockholders Equity | -10.06M | -7.88M | -7.86M | -2.92M | -2.59M |
Cash Flow | |||||
| Free Cash Flow | -481.24K | -779.35K | -566.35K | -504.43K | -672.29K |
| Operating Cash Flow | -455.38K | -779.35K | -550.79K | -504.43K | -672.29K |
| Investing Cash Flow | -25.86K | 0.00 | -15.56K | 0.00 | 0.00 |
| Financing Cash Flow | 499.20K | 781.99K | 544.97K | 419.81K | 739.86K |
Biosenta Inc Technical Analysis
Negative
0.08
Price Trends
0.08
Negative
0.09
Negative
0.11
Negative
Market Momentum
>-0.01
Positive
5.56
Positive
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ZRO, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.08, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 5.56 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ZRO.
Biosenta Inc Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
50 Neutral | C$4.33M | -0.55 | -70.53% | ― | -2.34% | -19.25% | |
43 Neutral | C$1.52M | -1.63 | -129.49% | ― | -95.69% | 44.32% | |
42 Neutral | C$1.74M | -1.38 | ― | ― | ― | ― | |
| ― | C$17.89M | -6.90 | -179.43% | ― | ― | -132.56% |
* Consumer Defensive Sector Average
TSE:ZRO
Biosenta Inc
0.05
-0.08
-61.54%
TSE:BGA
BioNeutra Global
0.03
-0.01
-25.00%
TSE:LFST
Lifeist Wellness
0.04
<0.01
14.29%
TSE:PSYC
Psyched Wellness
0.02
0.00
0.00%
TSE:MOOO.X
Happy Supplements Inc.
0.35
-0.37
-51.39%
TSE:URAI
Pure to Pure Beauty Inc.
0.17
0.07
70.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.